Alkermes stock price target raised to $42 from $40 at RBC Capital

Published 30/07/2025, 17:20
Alkermes stock price target raised to $42 from $40 at RBC Capital

Investing.com - RBC Capital has raised its price target on Alkermes (NASDAQ:ALKS) to $42.00 from $40.00 while maintaining a Sector Perform rating on the stock. Currently trading at $26.78, InvestingPro analysis suggests the stock is undervalued, with a P/E ratio of 12.57 and strong financial health metrics.

The price target adjustment follows Alkermes’ second-quarter 2025 earnings report released Wednesday morning, which showed strength across the company’s core commercial business with underlying prescription growth and favorable gross-to-net dynamics. The company maintains an impressive 84.42% gross profit margin and holds more cash than debt on its balance sheet. Get deeper insights into Alkermes’ financial performance with a comprehensive InvestingPro Research Report, part of our coverage of 1,400+ US stocks.

RBC Capital noted that the earnings call focused primarily on alixorexton, including discussions about endpoint selection, potential labeling implications, and upcoming data readouts, though limited new details emerged during the discussion.

The firm indicated that Alkermes management expressed confidence regarding secondary endpoints such as cataplexy, the adverse event profile including visual disturbances, and the company’s Phase III development plan for the drug.

Despite positive near-term business performance, RBC Capital characterized Alkermes as a "show-me" story heading into the World Sleep conference, particularly given competitive pressure from Takeda and Centessa in the orexin antagonist market, as well as the threat of generic competition to existing products.

In other recent news, Alkermes reported second-quarter financial results that surpassed analyst expectations, showcasing robust performance across its proprietary product portfolio. The company’s revenue exceeded forecasts by 12%, and Alkermes now anticipates reaching the high end of its guidance range for the full year 2025. Despite these strong results, BofA Securities adjusted its price target for Alkermes from $35 to $33, maintaining a Neutral rating on the stock. This adjustment reflects BofA’s outlook on the company’s growth prospects. Investors may find interest in these developments as they highlight both the company’s current financial strength and the cautious stance of analysts. These updates are part of recent developments concerning Alkermes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.